Vir Biotechnology Inc
Vir Biotechnology Inc (VIR) Options Open Interest
VIR options open interest is 9,504 contracts. The 2-week average daily volume is 269 contracts across the chain.
Read more
Monitoring VIR open interest helps you see where real money is positioned on Vir Biotechnology Inc's options and which strikes are attracting the most commitment from traders. Vir Biotechnology Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor VIR options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising VIR options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Vir Biotechnology Inc to settle.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where VIR open interest is concentrated. Our scanner maps Vir Biotechnology Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Vir Biotechnology Inc's options open interest as the signal it is, not as an afterthought.
| 11.00 | — | 0.55 | 0.55 | 314% | +0.5055 | 667 |
| 9.00 | 1.25 | 2.60 | 1.93 | 206% | +0.9874 | 508 |
| 10.00 | 0.25 | 0.95 | 0.60 | 23% | +1.0000 | 142 |
| 12.00 | — | 0.30 | 0.30 | 365% | +0.2999 | 102 |
| 13.00 | — | 0.75 | 0.75 | 776% | +0.3604 | 7 |
| 9.00 | — | 0.10 | 0.10 | 389% | -0.1066 | 530 |
| 8.00 | — | 0.30 | 0.30 | 786% | -0.1374 | 31 |
| 10.00 | — | 0.75 | 0.75 | 647% | -0.3241 | 23 |
| 11.00 | — | 1.00 | 1.00 | 513% | -0.4693 | 18 |
| 2.00 | — | 0.05 | 0.05 | 1,000% | -0.0000 | 1 |
As of September 17, 2026
Follow the money
Track VIR open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→